Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial.

[1]  K. Fowler,et al.  A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development , 2022, BMC Public Health.

[2]  J. Kurtzberg,et al.  Maternal Fc-mediated non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus infection , 2021, medRxiv.

[3]  J. Broach,et al.  Congenital Cytomegalovirus Infection Burden and Epidemiologic Risk Factors in Countries With Universal Screening , 2021, JAMA network open.

[4]  R. Rustandi,et al.  Characterization of gH/gL/pUL128-131 pentameric complex, gH/gL/gO trimeric complex, gB and gM/gN glycoproteins in a human cytomegalovirus using automated capillary western blots. , 2021, Vaccine.

[5]  D. Bernstein,et al.  Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans , 2020, Science Translational Medicine.

[6]  P. Griffiths,et al.  Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease. , 2020, The Journal of infectious diseases.

[7]  S. Permar,et al.  Impact of Maternal Immunity on Congenital Cytomegalovirus Birth Prevalence and Infant Outcomes: A Systematic Review , 2019, Vaccines.

[8]  J. Pollara,et al.  Humoral Immune Correlates for Prevention of Postnatal Cytomegalovirus Acquisition. , 2019, The Journal of infectious diseases.

[9]  R. Das,et al.  Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects. , 2019, The Journal of infectious diseases.

[10]  W. Britt,et al.  Cytomegalovirus Shedding in Seropositive Pregnant Women From a High-Seroprevalence Population: The Brazilian Cytomegalovirus Hearing and Maternal Secondary Infection Study , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  S. Boppana,et al.  Congenital cytomegalovirus infection. , 2018, Seminars in perinatology.

[12]  Wendy J M van Zuylen,et al.  Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. , 2017, The Lancet. Infectious diseases.

[13]  D. Vaidya,et al.  Cytomegalovirus Kinetics Following Primary Infection in Healthy Women , 2017, The Journal of infectious diseases.

[14]  J. Schiffer,et al.  Transient Oral Human Cytomegalovirus Infections Indicate Inefficient Viral Spread from Very Few Initially Infected Cells , 2017, Journal of Virology.

[15]  Jingyuan Xu,et al.  A replication-defective human cytomegalovirus vaccine for prevention of congenital infection , 2016, Science Translational Medicine.

[16]  D. Bernstein,et al.  Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial. , 2016, Vaccine.

[17]  R. DeBiasi,et al.  Valganciclovir for symptomatic congenital cytomegalovirus disease. , 2015, The New England journal of medicine.

[18]  T. Fu,et al.  Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. , 2014, Vaccine.

[19]  E. Ferrazzi,et al.  A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. , 2014, The New England journal of medicine.

[20]  J. Shiver,et al.  Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. , 2012, Vaccine.

[21]  D. Diamond,et al.  The immune response to human CMV. , 2012, Future virology.

[22]  M. Cannon,et al.  Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection , 2011, Reviews in medical virology.

[23]  Lawrence Corey,et al.  Vaccine prevention of maternal cytomegalovirus infection. , 2009, The New England journal of medicine.

[24]  S. Grosse,et al.  New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection , 2007, Reviews in medical virology.

[25]  M. Cannon,et al.  Review and meta‐analysis of the epidemiology of congenital cytomegalovirus (CMV) infection , 2007, Reviews in medical virology.

[26]  S. Soong,et al.  Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. , 2003, The Journal of pediatrics.

[27]  W. Britt,et al.  Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity , 2001, The New England journal of medicine.

[28]  P. Griffiths,et al.  Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. , 1999, The Journal of infectious diseases.

[29]  T. Morishima,et al.  Prophylactic oral acyclovir in outbreaks of primary herpes simplex virus type 1 infection in a closed community. , 1992, Pediatrics.

[30]  F. Henderson,et al.  Herpes simplex type 1 infections in group day care. , 1991, The Pediatric infectious disease journal.

[31]  S. Adler.  Cytomegalovirus and Child Day Care , 1989 .

[32]  M Nurminen,et al.  Comparative analysis of two rates. , 1985, Statistics in medicine.

[33]  I. Chan,et al.  Exact power and sample size for vaccine efficacy studies , 1998 .

[34]  M. Manning,et al.  Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. , 1995, The Journal of infectious diseases.